文献速递药物不良反应与药物警戒

PCSK9抑制剂与神经认知药物不良反应:EudraVigilance数据库个例安全报告分析

PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
PubMed 文献 · Drug Saf · 2020-12-22

基于EudraVigilance数据库分析以阿利西尤单抗或依洛尤单抗为可疑药物的个例安全报告,共2041例报告神经精神不良反应。两药在神经系统疾病报告概率上高于阿托伐他汀和氟伐他汀,在精神疾病报告概率上低于辛伐他汀、普伐他汀和瑞舒伐他汀,两药间无差异。

要点

  • 阿利西尤单抗或依洛尤单抗相关报告中22.7%为神经精神不良反应。
  • 两药神经系统疾病报告概率高于阿托伐他汀和氟伐他汀。
  • 两药精神疾病报告概率低于辛伐他汀、普伐他汀和瑞舒伐他汀。

核心结论

  • 阿利西尤单抗或依洛尤单抗为可疑药物的个例安全报告中22.7%描述了神经精神不良反应的发生。
  • 依洛尤单抗和阿利西尤单抗相比他汀类具有更高的神经系统不良反应报告概率。

研究设计与样本

  • 分析欧洲药物警戒数据库EudraVigilance中发送的个例安全报告,以阿利西尤单抗或依洛尤单抗为可疑药物且至少报告一项神经或精神不良反应。
  • 计算报告比值比(ROR)比较阿利西尤单抗、依洛尤单抗与他汀类报告神经精神不良反应个例安全报告的概率。

主要发现

  • 共2041例以阿利西尤单抗和/或依洛尤单抗为可疑药物的个例安全报告描述了神经精神不良反应的发生。
  • 两药最常报告的首选术语为头痛、失眠和抑郁。
  • 阿利西尤单抗与依洛尤单抗在神经系统疾病(ROR 1.02,95%CI 0.91-1.14)和精神疾病(ROR 1.12,95%CI 0.94-1.34)个例安全报告ROR间无差异。
  • 依洛尤单抗和阿利西尤单抗相比阿托伐他汀和氟伐他汀具有更高的神经系统疾病个例安全报告报告概率。
  • 依洛尤单抗和阿利西尤单抗相比辛伐他汀、普伐他汀和瑞舒伐他汀具有更低的精神疾病个例安全报告报告概率。

临床怎么用

  • 临床使用PCSK9抑制剂时应关注头痛、失眠和抑郁等神经精神不良反应的监测。
  • 与阿托伐他汀和氟伐他汀相比,PCSK9抑制剂神经系统不良反应报告概率更高,需结合患者情况评估。

局限性

  • 需要来自真实世界背景的进一步数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is) were associated with a risk of neurocognitive adverse drug reactions (ADRs). OBJECTIVE: We aimed to investigate the occurrence of neuropsychiatric ADRs related to PCSK9Is. METHODS: We analyzed Individual Case Safety Reports (ICSRs) sent through the European pharmacovigilance database that reported alirocumab or evolocumab as the suspected drug and at least one neurological or psychiatric ADR. The reporting odds ratio (ROR) was computed to compare the probability of reporting ICSRs with neuropsychiatric ADRs between alirocumab, evolocumab and statins. RESULTS: Overall, 2041 ICSRs with alirocumab and/or evolocumab as the suspected drug described the occurrence of neuropsychiatric ADRs. The most reported preferred terms for both drugs were headache, insomnia and depression. No difference between alirocumab and evolocumab was observed for the RORs of ICSRs with ADRs belonging to the System Organ Classes (SOCs) 'Nervous system disorders' or 'Psychiatric disorders' (ROR 1.02, 95% confidence interval 0.91-1.14; and 1.12, 95% CI 0.94-1.34, respectively), while evolocumab and alirocumab had a higher reporting probability of ICSRs with ADRs belonging to the SOC 'Nervous system disorders' compared with atorvastatin and fluvastatin. A lower reporting probability was instead found for ICSRs with ADRs belonging to the SOC 'Psychiatric disorders' for evolocumab and alirocumab versus simvastatin, pravastatin and rosuvastatin. CONCLUSION: Our results demonstrated that 22.7% of all ICSRs reporting alirocumab or evolocumab as suspect drugs described the occurrence of neuropsychiatric ADRs. The ROR showed that evolocumab and alirocumab had a higher reporting probability of neurological ADRs compared with statins. Further data from real-life contexts are needed.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. di Mauro G, Zinzi A, Scavone C, et al. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Saf. 2020. PMID: 33351170. doi:10.1007/s40264-020-01021-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。